Stop Competing on Price and Start Delivering VALUE!!!

FDA has approved Epclusa – New treatment for Chronic Hepatitis C

On June 28, 2016, FDA approved Gilead’s new drug, Epclusa, to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.

read more

Stay informed with our newsletter, publications and more!

I'd like to:

 receive newsletters

Tell us who you are: